MODULEX-GROUP
10.5.2021 09:02:09 CEST | Business Wire | Press release
Modulex Group announces today that current CEO Ketil M. Staalesen moves into a majority ownership role. This move, a long time in the making, will set Modulex up to achieve Staalesen’s goal of DKK 1 Billion in revenue and a Group EBITDA of 10%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005057/en/
A native Norwegian, Ketil is a citizen of the world, having lived in several countries worldwide, including Denmark, Germany, Spain, UK, Mexico and the US. He completed his MBA at EBCM Barcelona/Munich.
“This week marks my 20th anniversary at Modulex. I grew up in this company professionally, and I can’t think of a more fitting week to move into a majority ownership position and take Modulex into a new era.”
Modulex, founded by the LEGO Group, has been a Denmark headquartered company since 1963. With offices and factories around the world, Modulex is a global leader in visual communication solutions. Their capabilities started in manufacturing and evolved into architectural signage, Design + Build solutions, global rebranding and recently launched a line up of green products in a continuing effort to offer sustainable solutions to clients.
“I feel a great responsibility to honour the Danish roots and the founder, Godtfred Kirk Christiansen’s vision for Modulex. The company has weathered significant change over the decades, and thanks to my incredible team and personal commitment from Peter Thorsen, our position is very strong. I have always felt incredible support from the team,” says Staalesen. Thorsen, a trusted mentor and business associate to Staalesen, will stay on a minority partner.
“The future of Modulex is in excellent hands,” says Peter Thorsen. “I have had the pleasure of working and mentoring Ketil for many years and see him develop into the leader Modulex needs. His vision, passion and his ability to bring an idea into action will bring Modulex to a new level.”
For more information, visit modulex.com or contact media@modulex.com .
About Modulex:
Founded in 1963 by the LEGO group, Modulex is a global leader in visual communication and brand implementation. Rooted in Danish design excellence and a modular signage concept, Modulex has evolved its offering with design, wayfinding, exterior custom solutions, and brand implementations on a local or global scale. In 2019 the ISO9001 certified factory in Denmark created a sustainable product line and had been awarded the Green Network diploma for nine straight years. The multi-national group has five factories globally. It has a presence in over 300 cities across 45 countries, giving them infinite reach and the ability to deliver on its promise of global vision, local reach, and one company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom